Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:33:50.976Z.
Calculation as of: 2026-10-06T17:33:50.976Z.
Quote observation: 2026-10-06T17:30:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bd9bff75293b0061b415f76424971e71050022ba1ca13a61eeb09eda3fdb1614
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Rapport Therapeutics, Inc. Common Stock
Market Cap
$1.46B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.45B
Price/OCF Ratio
9.22
TTM Avg
9.60
3Y Avg
21.94
5Y Avg
276.98
Market Cap
$1.49B
Price/OCF Ratio
21.58
TTM Avg
21.79
3Y Avg
15.72
5Y Avg
18.04
Market Cap
$1.49B
Price/OCF Ratio
98.62
TTM Avg
58.20
3Y Avg
417.88
5Y Avg
357.25
Market Cap
$1.42B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rapport Therapeutics, Inc. Common Stock (RAPP) | $1.46B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.46B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 9.22 | 9.60 | 21.94 | 276.98 |
| Certara, Inc. (CERT)vs › | $1.44B | 17.42 | 12.61 | 22.38 | 32.95 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.43B | N/A | 7.14 | 7.14 | 7.14 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Phibro Animal Health Corporation (PAHC)vs › | $1.49B | 21.58 | 21.79 | 15.72 | 18.04 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.49B | 98.62 | 58.20 | 417.88 | 357.25 |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.41B | 26.45 | 22.09 | 27.32 | 28.27 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
